Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | MIF | P14174 | 8/20 | 0.74 |
| ▸ | CD74 | P04233 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805679 | 0.85 | KMT2A (1.00) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL10874258 | 0.85 | MIF (1.00) | KMT2APOLBMEN1MIFCD74 | |
| SCHEMBL31499247 | 0.85 | IDO1 (0.81) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL29566285 | 0.85 | MIF (1.00) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL13086565 | 0.85 | KMT2A (0.81) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL2757836 | 0.85 | MIF (1.00) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL2757851 | 0.82 | MIF (1.00) | KMT2APOLBMEN1MIFCD74 | |
| SCHEMBL18805678 | 0.81 | MIF (0.79) | KMT2APOLBMEN1MIFCD74 | |
| SCHEMBL2544345 | 0.80 | KMT2A (0.72) | IDO1KMT2APOLBMEN1MIF | |
| SCHEMBL14563196 | 0.80 | POLB (0.72) | KMT2APOLBMEN1MIFCD74 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | claimed |
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2023-12-21 | — | — | US | disclosed |
| EP-4237002-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | University Health Network (CA) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022087719-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404980-A1 | METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF | MIF, SPAST, MMP12 | IDO1 602/4885KMT2A 2744/4885POLB 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.